![Alternative splicing in the C-terminal region of nuclear receptors.\
A schematic view of the three commonly used alternative splicing mechanisms for the generation of C-terminal splice variants of nuclear receptors. A: exon replacement. Replacing the final exon(s) of the canonical receptor with an alternative exon and 3'UTR results in a unique protein ending. B: Intron retention. An intronic sequence is not spliced out when producing the mRNA, resulting in a premature stop codon and a unique C-terminal ending. C. Alternative acceptor site usage. An alternative splice acceptor site inside an exon is used, which results in a frame shift and an alternative C-terminal end of the protein.](nrs07007.f1){#fig1}

![Comparison of the secondary structure at the C-terminal end of canonical receptors and their splice variants.\
Predictions of the secondary structure of canonical NRs and their respective splice variants are shown at the C-terminal end of the LBD. Helices are indicated by boxes (with addition of the helix number), while random coil (or beta sheet) is indicated by a line. The divergence points are marked with a dotted line, while color differences indicate sequential differences between the canonical receptor and its splice variant.](nrs07007.f2){#fig2}

![Comparison of the secondary structure of canonical receptors and their splice variants\
Predictions of the secondary structure of canonical NRs and their respective splice variants are shown at whole protein level. The region of the DBD is indicated as a reference point. Helices are indicated by boxes, while random coil (or beta sheet) is indicated by a line. The divergence points are marked with a dotted line, while color differences indicate sequential differences between the canonical receptor and its splice variant.](nrs07007.f3){#fig3}

![Three possible mechanisms for the dominant-negative activity of C-terminal splice variants of nuclear receptors.\
In the left panel, transactivation by nuclear receptors is shown in the absence of an inhibitor. Nuclear receptors can bind to their response elements as a homodimer, a heterodimer (e.g., with RXR), or as a monomer. In the right panel, transactivation is inhibited due to the presence of a dominant-negative inhibitor, that either occupies the response elements (1), forms transcriptionally-inactive heterodimers with the canonical receptor (2), or competes for binding with transcriptional coactivator proteins (3).](nrs07007.f4){#fig4}

###### Overview of naturally occurring C-terminal splice variants of nuclear receptors.

All thirteen C-terminal splice variants described in this review are listed, as well as the splicing mechanism generating them (see also Figure 1 and Supplementary File 1), and the number of amino acids lacking from the canonical receptor and the number of variant-specific amino acids in their C-terminus. ^1^ Absence in mouse demonstrated experimentally. ^2^ Occurrence only demonstrated experimentally in rat/mouse, not in humans, but most likely conserved between humans and rodents, based on comparison of genomic sequence. ^3^ Presence in mouse/rat demonstrated experimentally. ^4^ ER: exon replacement; IR: intron retention; AA: alternative acceptor site usage (see Figure 1). ^5^ Could not be determined, due to lack of goldfish genomic sequence data.
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###### Splice variant-specific C-terminal amino acid sequences.

The table shows the variant-specific amino acid sequences in the C-termini of all thirteen nuclear receptor C-terminal splice variants described in this review.
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Introduction
============

Molecular mechanisms of nuclear receptor functioning
----------------------------------------------------

The nuclear receptor (NR) superfamily contains transcriptional regulators that are conserved throughout various metazoan species, such as nematodes, insects, and vertebrates \[[@r67]\]. There are several molecular mechanisms via which NRs can influence transcription.

The first mechanism involves unliganded receptors that are bound in a complex with heat-shock proteins (HSPs). The interaction with heat-shock proteins prevents the NR from entering the nucleus and thus ensures its localization in the cytosol. The ligand-binding domain (LBD) of the receptor undergoes a conformational change upon ligand binding, which results in dissociation from the heat-shock protein complex. Furthermore, this conformational change exposes the nuclear localization signal (NLS) and activation function 2 (AF2) domain that are present in the LBD. After translocation of the ligand-receptor complex to the nucleus, it forms homodimers or heterodimers with other NRs and binds with high affinity to nuclear receptor response elements (NREs) in the promoter regions of target genes. Subsequent recruitment of cofactors creates a DNA-bound complex that is capable of remodeling the chromatin structure and influencing transcription. Usually, this influence is positive and results in an upregulation of target genes, but most NRs are also capable of transcriptional repression through this mechanism. The mechanism described above is the prevalent model for transcriptional activation by steroid receptors, like the glucocorticoid receptor (GR) and estrogen receptor (ER) \[[@r18]; [@r41]; [@r60]\].

Nuclear receptors that function via the second mechanism bind constitutively to their NRE, even in the absence of ligands. This group includes receptors for the thyroid hormone, vitamin D and retinoic acid, and they are known to form heterodimers with retinoid X receptors (RXRs). Without ligand present, this NR-RXR heterodimer is bound to the response element in a complex with corepressor proteins. Therefore, receptors from this group function as active transcriptional repressors in the absence of ligand. After ligand binding, receptors undergo a conformational change which removes the corepressor proteins and replaces them with coactivator proteins. The removal of the corepressor proteins is thought to be an active process, which requires ubiquitination- and proteasome-dependent mechanisms. Similar to the first NR transcriptional activation mechanism, the recruited coactivators can make the chromatin structure more accessible and facilitate the assembly of the general transcriptional machinery at the promoter \[[@r18]; [@r41]; [@r60]\].

The majority of the so-called orphan receptors (receptors for which no ligand has been identified (yet)) bind to DNA as monomers. The methods via which orphan receptors regulate transcription are not as thoroughly investigated as for other nuclear receptors. However, orphan receptors might affect transcription through changes in their expression or via posttranslational modifications. These modifications include the phosphorylation or sumoylation of receptors via GPCRs (G-protein-coupled receptors), MAPKs (mitogen-activated protein kinases), and PKA (cAMP-dependent protein kinase). It is also possible that orphan receptors are activated by ligands that are yet to be discovered.

Besides activating or repressing genes via binding to NREs present in promoter regions, some NRs can also influence transcription via a mechanism called transrepression, which does not require DNA-binding of the receptor. Instead, this form of negative regulation seems to be mediated by inhibiting the activity of other transcription factors via direct physical interaction. Examples of transcription factors that are affected by transrepression are members of the nuclear factor-κB (NF-κB) and activator protein 1 (AP1) families. Both these families of transcription factors play crucial roles in pro-inflammatory signaling pathways and are of great interest in the treatment of immunity-related diseases \[[@r18]; [@r41]; [@r60]\].

Naturally occurring C-terminal splice variants of nuclear receptors
-------------------------------------------------------------------

Alternative mRNA splicing in the region encoding the C-terminal end of nuclear receptors results in receptor variants that lack one or more helices of the LBD, which are replaced by an alternative amino acid sequence unique to the splice variant. In this review, we present a literature study on these LBD splice variants, which reveals that out of forty-eight nuclear receptor genes encoded by the human genome, at least nine display this type of alternative splicing, and that in other species, several different C-terminal splice variants occur, which may occur in humans, as well. None of these receptor variants appear to be able to bind ligand and to induce transcription on promoters containing the response element for the respective canonical receptor variant. Interestingly, almost all LBD splice variants have been shown to display dominant-negative activity on the transactivational properties of their canonical equivalent.

Although these receptor variants are highly comparable in structure and function, the available literature on these proteins is very scattered. They have never been described as a group before, and articles on one C-terminal splice variant hardly ever cite work on a similar splice variant of another receptor. Therefore, we would like to provide a broader perspective on C-terminal splice variants, by considering them as a group of proteins, rather than individually. The aim of this review is to provide a structural and functional comparison of these potential dominant-negative nuclear receptors, which could lead to a better understanding of their function *in vivo* and the molecular mechanisms underlying their activity. Unfortunately, most of these splice variants have been poorly studied, so only limited data are available. The member of this group that has been studied in most detail is the β-isoform of the glucocorticoid receptor. By reviewing the literature on this splice variant, we would like to shed light on the possible *in vivo* function and relevance of nuclear receptor C-terminal splice variants in general.

The ligand-binding domain of nuclear receptors
----------------------------------------------

The LBD of nuclear receptors is involved in several processes required for transcription initiation, like ligand binding, binding to coactivator proteins, and dimerization. Most nuclear receptor LBDs are comprised of 12 α helices, which are arranged in a three-layer sandwich \[[@r6]; [@r39]; [@r80]\]. Helices 1-3 form one outer layer of the sandwich and helices 6, 7 and 10 form the other outer layer. Helices 4, 5, 8, and 9 form the middle layer, which is absent in the bottom half of the sandwich, thereby creating a cavity for ligand binding in most receptors. Upon ligand binding, a conformational change occurs, which depends on the nature of the ligand. When an agonist is bound, helix 12, which contains the AF-2 domain, is packed against helices 3 and 10 and becomes an integral part of the LBD. Thereby, it closes the binding pocket and forms, together with helix 3, 4 and 5, a binding surface for coactivator proteins \[[@r78]\]. Coactivators that contain an LXXLL amino acid motif can interact with this surface \[[@r63]\], enabling optimal transcription initiation by the nuclear receptor. In most nuclear receptors, LBD-dependent receptor dimerization is mediated by the N-terminal half of helix 10, which packs against the same domain in its dimerization partner. In the resulting dimer, the two helix 10 subunits form a coiled-coil structure. Finally, the (non-helical) most C-terminal part of the LBD is variable in length and sequence for different receptors and is called the F-domain. The precise function of this domain remains unclear \[[@r41]\], but it has been suggested that it stabilizes the conformational state of the LBD when ligand is bound \[[@r33]; [@r60]\].

The occurrence of C-terminal splice variants of nuclear receptors
=================================================================

In this section, thirteen C-terminal splice variants of nuclear receptors will be described, which are listed in [Table 1](#table-fn1){ref-type="table"}. Nine splice variants have been demonstrated to occur in humans: the glucocorticoid receptor β (GRβ), estrogen receptor βcx (ERβcx), thyroid hormone receptor α1 (TRα1), constitutive androstane receptor (sv5) (CAR(sv5)), dosage-sensitive sex reversal-1α (DAX-1α), nuclear receptor related 2 (Nurr2), neuron-derived orphan receptor-2 (NOR-2), peroxisome proliferator-activated receptorα~tr~ (PPARα~tr~), and the PPARγ isoform γORF4. One splice variant has been shown to occur in rats (vitamin D receptor 1 (VDR1)), one in mouse (CAR2), and in fish two splice variants named identical to their human equivalents exist (GRβ in zebrafish and TRα1 in goldfish), but most likely, they have evolved independently.

There are three mechanisms which are commonly used for the generation of C-terminal splice variants of nuclear receptors ([Figure 1](#fig1){ref-type="fig"}). With all three mechanisms, most of the resulting protein sequence is identical between the canonical receptor and the splice variant, but a C-terminal sequence is different. This difference can be a result of an alternative exon replacing the most 3' exon(s) of the mRNA encoding the canonical receptor. This mechanism is called exon replacement ([Figure 1](#fig1){ref-type="fig"}A). Alternatively, an intronic sequence may be retained as an exon which replaces the most 3' exon ([Figure 1](#fig1){ref-type="fig"}B). Finally, an alternative splice acceptor site inside an exon may be used, which results in a frame shift and an alternative C-terminal end of the protein ([Figure 1](#fig1){ref-type="fig"}C). In all three cases, the sequence replacing the final exon(s) of the canonical receptor contains a sequence encoding a unique C-terminus with no homology to the C-terminus of the canonical receptor. The generation of TRα2 is more complicated and involves a combination of alternative splice donor site usage and exon replacement. The precise splicing mechanisms for all variants are depicted in [Supplementary File 1](#supplementary-material1){ref-type="supplementary-material"}.

The first group (consisting of hGRβ, hERβcx, rVDR1, mCAR2/hCAR(sv5), and hDAX-1α) has a point of divergence between the splice variant and the canonical receptor in the region close to helix 10. The transcripts encoding these receptor variants lack only the final exon of the canonical receptor mRNA (apart from the mCAR2 mRNA, which lacks two exons), which encodes in most cases between 50 and 100 amino acids. In the second group (consisting of hNurr2, hNOR-2, hPPARα~tr~ and hγORF4), a significant part of the LBD (at least 200 amino acids), which in most cases spans almost the entire LBD, is replaced by an alternative sequence. The mRNA encoding these splice variants lacks two to four exons of the canonical messenger. In [Figure 2](#fig2){ref-type="fig"} and [Figure 3](#fig3){ref-type="fig"}, a schematic representation of the structures of all splice variants is shown, indicating the divergence points between the canonical receptor and the splice variant and their predicted secondary structures. The amino acid sequences of the different variant-specific C-termini are shown in [Table 2](#table-fn2){ref-type="table"}.

Variants of the glucocorticoid receptor (GR)
--------------------------------------------

Glucocorticoids (GCs) are a class of steroid hormones that are essential in the maintenance of homeostasis and enable the organism to respond to both physical and emotional stress. GCs are capable of stimulating metabolism, while they attenuate immune and inflammatory processes \[[@r7]\]. In 1985, two human GR (hGR) isoforms were identified and named hGRα and hGRβ. The canonical receptor, hGRα only differs from the hGR β-isoform at its C-terminal end. The first 727 amino acids are identical for hGRα and hGRβ, after which hGRα has an additional 50 amino acids and hGRβ has an additional, non-homologous 15 amino acids \[[@r2]; [@r48]\]. The *hGR* gene contains 10 exons: exons 1-8, followed by two copies of exon 9 (exon 9α and 9β for hGRα and hGRβ, respectively). Alternative splicing between the eighth and the ninth exon replaces the canonical exon 9α with exon 9β, which leads to the generation of a mRNA encoding hGRβ \[[@r2]; [@r48]\]. This splicing event results in the absence of helix 12 and part of helix 11 of the LBD in hGRβ, which is replaced by a unique C-terminal end \[[@r84]\].

The hGR β-isoform has been detected in a variety of human cell lines and tissues \[[@r48]\]. At the mRNA level, hGRβ expression is significantly lower than the expression of hGRα \[[@r11]; [@r45]; [@r48]\]. However, this difference is not observed at the protein level, at which a higher hGRβ expression level is detected in some cells (e.g., human neutrophils), as compared to hGRα \[[@r12]; [@r69]\]. Experiments concerning the expression levels of hGRα and hGRβ revealed that mRNA transcripts for both hGR isoforms are present at a ratio of at least 200:1 in different tissues \[[@r48]\]. Nevertheless, regional or cellular ratios can differ dramatically from this overall ratio. Furthermore, hGRβ shows a different subcellular localization than hGRα. While unliganded hGRα resides in the cytoplasm and only translocates to the nucleus upon ligand binding, hGRβ is constitutively present in the nucleus \[[@r49]\].

The alternatively spliced GR β-isoform is not present in rodents, due to the absence of the required splice site \[[@r54]\]. So far, the zebrafish is the only other organism in which the occurrence of a GR β-isoform has been demonstrated \[[@r64]\]. Like humans, the zebrafish genome contains one *GR* gene, and the pre-mRNA can be alternatively spliced into a zGRα (the canonical receptor) and a zGRβ messenger. The structure and the expression levels of zGRβ are strikingly similar to its human equivalent \[[@r64]\]. The zGRβ protein is identical to zGRα for the first 697 amino acids, after which it contains 40 unique amino acids. Protein alignment revealed that the divergence point between zGRα and zGRβ is located at the exact same position as for hGRα and hGRβ. The two divergence points are located in helix 11 of the LBD, resulting in an alternative ending of helix 11 and the absence of helix 12 for both hGRβ and zGRβ \[[@r19]; [@r23]\]. The 40 unique C-terminal amino acids of zGRβ show little homology to the additional 15 amino acids present in hGRβ \[[@r64]\]. As for hGRβ, zGRβ is expressed at a much lower level than the canonical receptor isoform, with ratios of zGRα:zGRβ varying from 20:1 to 146:1 \[[@r64]\]. The subcellular localization of zGRα and zGRβ is similar to the localization of their human homologs. Unliganded zGRα is located in the cytosol, while zGRβ is constantly present in the nucleus \[[@r64]\].

Although the protein structure of zGRβ closely resembles that of hGRβ, the splicing event leading to the formation of the GRβ isoforms is different for humans and zebrafish. For the human β isoform, its unique C-terminal sequence is encoded in an alternative version of exon 9, called exon 9β, which is located downstream of exon 9α. In the zebrafish genome, the unique sequence of GRβ is located in intron 8. Therefore, hGRβ is created by alternative exon usage, while zGRβ results from retention of part of intron 8 \[[@r64]\]. It is likely that zGRβ evolved independently of hGRβ, since the genetic organization and β-specific C-terminus of the human and zebrafish isoforms are different. Therefore, the presence of GRβ in humans and zebrafish is most likely a case of convergent evolution, which suggests a significant role for this isoform in these species.

Variants of the estrogen receptor (ER)
--------------------------------------

Estrogens are steroid hormones that play key roles in development and maintenance of normal sexual and reproductive functions in both men and women \[[@r24]\]. They also exert a vast range of biological effects in the cardiovascular, musculoskeletal, immune, and central nervous system. The most potent estrogen produced *in vivo* is 17β-estradiol \[[@r24]\]. The two nuclear receptors via which estrogens signal are named ERα and ERβ. Multiple isoforms exist for both ERα and ERβ as a result of alternative splicing \[[@r36]\]. One of the ERβ isoforms is the C-terminally truncated ERβcx (also known as ERβ2) \[[@r50]\]. ERβcx is identical to ERβ for the first 469 amino acids, but the final 61 amino acids of ERβ are replaced by a unique 26 amino acid sequence in Erβcx \[[@r50]\]. The canonical ERβ is encoded by 9 exons. Alternative splicing replaces the final *ERβ* exon (named L4) by an exon which is specific for ERβcx (named Lcx). The splicing mechanism used to create ERβcx is exon replacement (exon L4 is replaced by exon Lcx \[[@r50]\]).

ERβcx is primarily expressed in testis, ovary, prostate, and thymus. The relative expression levels of ERβcx and ERβ vary per tissue \[[@r36]\]. ERβcx is expressed at higher levels than ERβ in testis, while ERβ expression exceeds ERβcx expression in ovary \[[@r36]\]. Ogawa et al. \[[@r50]\] predict that a homolog for ERβcx might also exist for ERα. However, this type of ERα isoform has yet to be discovered.

Variants of the thyroid hormone receptor (TR)
---------------------------------------------

Thyroid hormones are regulators of physiological functions, such as the control of body temperature and heart rate. Following the secretion of thyroid stimulating hormone, circulating T~4~ is converted into T~3~, which is the active form of thyroid hormone \[[@r83]\]. Thyroid hormones signal via thyroid hormone receptors (TRs) present in the nucleus of cells. The two receptors that mediate T~3~-regulated gene expression are named TRα and TRβ \[[@r83]\]. The human *TRα* and *TRβ* genes both encode several receptor variants due to alternative promoter usage and alternative splicing. The different TRα and TRβ variants are highly homologous in human, rat and mouse \[[@r82]\]. One of the TRα isoforms that is generated by alternative splicing was named hTRα2 when it was isolated from a human cDNA library by Benbrook and Pfahl \[[@r4]\]. It differs from the canonical TRα receptor, hTRα1, at its C-terminal end. The human *TRα* gene contains a total of 10 exons. Usage of a splice donor site in exon 9 (approximately 128 bp downstream of the start of this exon) and an acceptor site at the 5' end of exon 10 results in a protein in which the 40 most C-terminal amino acids of hTRα1 are replaced by 120 amino acids specific for hTRα2 \[[@r71]\].

Mitsuhashi et al. \[[@r42]\] demonstrated that an isoform generated in a similar fashion as hTRα2 also exists in rats. They identified two transcripts that differ from the 410 amino acids long canonical rTRα receptor in their C-terminal region. Both these isoforms, 452 and 372 amino acids long, respectively, are generated by alternative splicing of the rat *TRα* gene. The longest isoform is spliced at the same location as hTRα2, and also replaces the final 40 amino acids of the canonical receptor with a unique C-terminal end \[[@r42]\].

C-terminal splice variants of TRα have also been identified in goldfish. Nelson and Habibi \[[@r46]\] analyzed goldfish cDNA for the occurrence of alternative TR transcripts and found two alternatively spliced TRα isoforms. The two truncated goldfish TRα (gTRα) isoforms were named TRα2 and TRα-truncated. gTRα-truncated is only 206 amino acids long, and similar to the canonical gTRα1 (466 amino acids) until the hinge region \[[@r46]\]. gTRα2 is similar to gTRα1 for the first 324 amino acids, after which the final 142 amino acids of gTRα1 are replaced by 54 variant-specific amino acids in gTRα2 \[[@r46]\]. The hTRα2 and gTRα2 isoforms are similar in that they both lose homology with their respective TRα1 counterparts in the C-terminal region of the LBD. Nevertheless, hTRα2 and gTRα2 are spliced in different regions of the *TRα* gene, and have different C-terminal endings. Unfortunately, the complete genomic sequence of the goldfish *TRα* gene is unknown, which makes it difficult to describe the splicing event leading to gTRα2 in detail.

Variants of the vitamin D receptor (VDR)
----------------------------------------

The biologically-active metabolite of vitamin D is called 1,25-dihydroxyvitamin D~3~ (further referred to as vitamin D~3~). Vitamin D~3~ is important in the metabolism of minerals, and in the formation and growth of bone \[[@r13]\]. The biological actions of vitamin D~3~ are mediated by the vitamin D receptor (VDR). In the rat, a VDR isoform has been identified which differs from the canonical receptor at its C-terminal end \[[@r15]\]. Alternative splicing generates an isoform which has retained intron 8 of the canonical rat vitamin D receptor (rVDR0). A stop codon within intron 8 truncates the C-terminal region of this isoform (named rVDR1). As a result, rVDR1 lacks the most C-terminal 86 amino acids of rVDR0. These amino acids are replaced by 19 variant-specific amino acids. Analysis of the genomic structure and sequence of the *rVDR* gene demonstrated that the inserted sequence corresponds to the entire intron between exon 8 and 9 \[[@r15]\]. The rVDR1 transcript is expressed at 1/15th to 1/20th of the level of rVDR0 expression \[[@r15]\]. Both rVDR0 and rVDR1 are primarily expressed in the intestines and the kidney, and rVDR1 was only detected in mature rats, not in embryos \[[@r15]\].

To date, a dominant-negative VDR isoform has only been identified in rats. However, allelic variations in intron 8 of the *hVDR* gene can be used to predict the density of bone \[[@r15]\]. Intron 8 of the *hVDR* gene corresponds to the intron that is retained in the *rVDR* gene for the formation of rVDR1. Therefore, a similar splicing mechanism may exist for the *hVDR* gene.

Variants of the constitutive androstane receptor (CAR)
------------------------------------------------------

The constitutive androstane receptor (CAR) was originally identified as an orphan receptor. Later, CAR was found to act as a receptor for foreign compounds, known as xenobiotics \[[@r72]\]. Together with the pregnane X receptor (PXR), CAR performs a pivotal role in hepatic drug metabolism. To date, no definitive physiological ligand has been identified for CAR. Instead, CAR responds to a range of toxic by-products of endogenous metabolism and to exogenous chemicals \[[@r72]\]. The genetic organization of CAR has been studied in humans and mice. Both genes contain 9 exons and share a high degree of sequence similarity throughout the DNA-binding and ligand-binding domain \[[@r9]\]. The human *CAR* gene can generate a C-terminally spliced receptor isoform. The canonical hCAR is 352 amino acids long, while the truncated hCAR splice variant 5 (hCAR(sv5)) isoform is only 317 amino acids long \[[@r1]\]. Alternative splice acceptor site usage in exon 9 leads to a deletion of the first 76 base pairs of this exon. Consequently, the final 42 amino acids of hCAR are replaced by 7 amino acids, which are specific for hCAR(sv5) due to a frame shift \[[@r1]\].

The canonical human CAR (hCAR) is expressed in the liver, kidney, spleen, testis, and small intestines. In contrast, the hCAR(sv5) isoform was shown to be present in every tissue studied, with the exception of the small intestine \[[@r1]\]. Therefore, most tissues only contain the truncated hCAR(sv5) isoform. The subcellular localization of hCAR(sv5) is similar to that of hCAR \[[@r1]\].

In mouse, the canonical CAR is named mCAR1. A C-terminal splice variant, named mCAR2, is identical to mCAR1, except for the most C-terminal 78 amino acids present in mCAR1 \[[@r9]\]. These amino acids are replaced by 6 variant-specific amino acids in mCAR2 \[[@r9]\]. The mCAR2 isoform is generated by replacement of exon 8 and 9 with an alternative exon that is located between these exons \[[@r9]\]. The mouse CAR1 and CAR2 are primarily expressed in the liver. Compared to the expression of mCAR1, the mCAR2 variant is expressed at relatively low levels \[[@r9]\].

Variants of dosage-sensitive sex reversal-1 (DAX-1)
---------------------------------------------------

The orphan nuclear receptor named dosage-sensitive sex reversal-1 (DAX-1) provides another interesting example of the generation of a C-terminal receptor splice variant. DAX-1 plays an important role in the development and functioning of the adrenal gland and the hypothalamic-pituitary-adrenal axis \[[@r28]\]. Furthermore, DAX-1 is a transcriptional repressor of several genes involved in steroid hormone metabolism and acts as a corepressor of steroidogenic factor 1 (SF-1), ERα, and ERβ \[[@r28]\]. DAX-1 is an unusual nuclear receptor, since it is encoded by only two exons and lacks the characteristic zinc-finger DNA-binding motif that is highly conserved in other nuclear receptors \[[@r28]\]. The human *DAX-1* gene generates two distinct isoforms via the usage of an alternative version of the second exon \[[@r28]\]. The mRNA encoding the canonical receptor, DAX-1, combines exon 1 with the normal version of exon 2 to generate a protein that contains 470 amino acids. Combining exon 1 with the alternative exon 2a results in the generation of DAX-1α (401 amino acids long), which contains a unique C-terminal sequence compared to DAX-1.

The canonical DAX-1 receptor is expressed in the adrenal gland, brain, fetal kidney, ovary, pancreas, and testis. DAX-1α is also present in these tissues, but was also detected in all other human tissues which were examined \[[@r28]\]. DAX-1α is expressed at higher levels than DAX-1 in all tissues, except in the testis, where DAX-1 expression is higher \[[@r28]\]. So far, this DAX-1 splice variant has only been discovered in humans.

Variants of the nuclear receptor related 1 (Nurr1)
--------------------------------------------------

The NGFI-B family of nuclear receptors consists of NGFI-B, Nurr1, and NOR1. All three members of the NGFI-B family are orphan receptors, since no ligands have been identified yet \[[@r51]\]. These receptors have been implicated in many biological processes, such as neural differentiation, cell growth, and T-cell apoptosis \[[@r51]\]. Nevertheless, little is known about the molecular mechanisms via which they affect these processes \[[@r51]\].

The mouse *Nurr1* gene contains 8 exons, of which the first two are non-coding \[[@r62]\]. A C-terminally truncated variant of mouse Nurr1 is named Nurr2 \[[@r51]\]. The most C-terminal amino acids of Nurr2 are derived from alternative usage of a splice acceptor site in exon 6, ending in an in-frame stop-codon. In addition, Nurr2 is generated by alternative splicing in exon 1 and 2, resulting in a shorter N-terminal region, as well. The occurrence of Nurr2 is conserved in at least mouse, rat, and human \[[@r51]\]. Nurr1 and Nurr2 are expressed ubiquitously in all examined tissues in these species \[[@r51]\]. In each tissue, Nurr2 is expressed at significantly lower levels than Nurr1.

Variants of the neuron-derived orphan receptor-1 (NOR-1)
--------------------------------------------------------

A C-terminal splice variant also exists for the NGFI-B family member NOR-1, which is named NOR-2 \[[@r57]\]. NOR-2 has so far been found in humans \[[@r52]\], rat \[[@r57]\] and mouse \[[@r40]\]. The full-length hNOR-1 is 626 amino acids long, while hNOR-2 only contains 443 amino acids. hNOR-2 is generated by retention of the intron between exon 5 and 6, which contains a premature stop-codon and the 3'UTR. The mRNA encoding hNOR-2 lacks exons 6, 7, and 8 \[[@r40]\]. The variant-specific amino acid sequence is 10 amino acids long in mouse and rat and 25 amino acids long in humans \[[@r52]\].

Variants of the peroxisome proliferator-activated receptor α (PPARα)
--------------------------------------------------------------------

The peroxisome proliferator-activated receptors (PPARs) are ligand-dependent receptors involved in lipid homeostasis, energy metabolism, inflammation, and cellular differentiation and proliferation \[[@r31]\]. Endogenous ligands for the PPARs include free fatty acids and eicosanoids.

There are three PPARs: PPARα, PPARβ (also known as PPARδ), and PPARγ. A splice variant within the C-terminal region of the human PPARα has been described and named PPARα~tr~ \[[@r17]; [@r55]\]. PPARα is encoded by 7 exons and is 468 amino acids long, whereas PPARα~tr~ is only 174 amino acids long. PPARα~tr~ mRNA is generated by retention of the intronic sequence at the 3' end of exon 5. PPARα~tr~ mRNA lacks exon 6, 7 and 8 \[[@r21]; [@r43]\]. PPARα~tr~ mRNA is expressed in several human tissues and represents 20-50% of total PPARα mRNA \[[@r17]; [@r55]\]. PPARα~tr~ has only been identified in humans.

Variants of the peroxisome proliferator-activated receptor γ (PPARγ)
--------------------------------------------------------------------

The *PPARγ* gene consists of 6 exons and a C-terminal splice variant, γORF4, is generated by retention of intronic sequence at the 3' end of exon 4 \[[@r31]; [@r61]\]. The final two exons of the mRNA encoding the canonical receptor, exons 5 and 6, are deleted from the transcript. This results in a protein that is identical to PPARγ for the first 243 amino acids and contains 21 additional amino acids coded for by intron 4 sequences \[[@r31]; [@r61]\]. Like PPARα~tr~, γORF4 has only been identified in humans.

The function of C-terminal splice variants of nuclear receptors
===============================================================

Loss of ligand binding and transactivation activity
---------------------------------------------------

Binding to cognate ligand has not been reported for any of the described nuclear receptor splice variants. As is known from structural studies, the C-terminal region of the LBD that is lacking in these variants is required for ligand binding and apparently, the variant-specific C-terminal amino acids do not have the characteristics to fulfill this role.

In addition to the lack of ligand binding ability, all described splice variants lack the ability to transactivate gene transcription induced by a promoter containing their cognate response element. This has been shown in experiments with reporter assays using transient transfection of the reporter plasmid. For the non-orphan receptors, this obviously could be explained by the inability to bind ligand and become activated. However, all described receptor variants also lack the AF-2 containing C-terminal helix of the LBD, which is replaced by an alternative C-terminus. The inability to transactivate may therefore also be due to the variant-specific C-terminal sequence not having the characteristics to substitute for the function of the AF-2 domain, with the result that the surface required for the docking of LXXLL-motif-containing coactivators cannot be formed. Moreover, the alternative C-terminus apparently keeps the receptor variant in a conformation that does not allow the AF-1 to be functional, since this domain, together with an intact DNA-binding domain (DBD), can be sufficient for transactivation activity in reporter assays \[[@r26]\].

Dominant-negative activity
--------------------------

Ten splice variants described have been shown to act as dominant-negative inhibitors of the activity of their respective canonical receptor. In most cases, this has been demonstrated in reporter assays in which the canonical receptor, the splice variant and a plasmid containing a reporter gene (CAT or luciferase) driven by a promoter containing the response element for the respective receptor, were transiently transfected into cultured cells. The only splice variant that fails to show dominant-negative activity in such an assay is the mouse CAR2 isoform, which does not inhibit the transactivation properties of mCAR1 \[[@r9]\]. The possible dominant-negative activity of the human CAR splice variant hCAR(sv5) and the goldfish TRα2 was not studied, and the dominant-negative activity of DAX-1α was studied in a different assay. DAX-1α was demonstrated to inhibit the ability of the canonical receptor DAX-1 to repress SF-1-induced transactivation in transiently transfected reporter assays \[[@r28]\].

The dominant-negative activity of hGRβ appears to depend on two amino acids (a lysine and a proline), which are present in the hGRβ-specific C-terminal 15 amino acid sequence, rather than on the absence of the AF-2 containing helix 12 \[[@r84]\]. It has been shown that these two amino acids play a role in the nuclear localization of hGRβ \[[@r84]\].

The dominant-negative activity of the splice variant is not always specifically affecting the activity of the respective canonical receptor, but may affect other members of the nuclear receptor family, as well. mNurr2 inhibits transactivation of all members of the NGFI-B family \[[@r51]\]. hTRα2 shows dominant-negative activity on hTRα1 and hTRβ, but also on hRARβ and hER-induced transactivation on the same (TRE-driven) promoter \[[@r25]\]. hPPARα~tr~ shows inhibition of hPPARα, hPPARγ, hHNF-4, hRORα and hGRα \[[@r17]\]. hERβcx shows dominant-negative activity on hERα (surprisingly, not on hERβ-induced transactivation \[[@r50]\]). In contrast, rVDR1 seems to specifically inhibit rVDR0, since it has been demonstrated not to inhibit transactivation induced by the closely related receptors TR and RAR on promoters containing their cognate response elements \[[@r15]\]. hGRβ shows dominant-negative activity over hGRα and hMR \[[@r2]; [@r3]; [@r48]\], but not over hAR- and hPR-induced transactivation \[[@r48]\], whereas all four receptors are able to induce transcription on the same response element.

Mechanism of action of dominant-negative activity
-------------------------------------------------

Three mechanisms via which receptor variants with dominant-negative activity can interfere with canonical receptor signaling have been proposed \[[@r82]\], and they are shown in [Figure 4](#fig4){ref-type="fig"}.

### Occupation of response elements

The first mechanism involves competition for DNA binding on NREs by dominant-negative receptors. In this case, competition for a limited amount of NREs results in a reduced transcriptional activity of the canonical receptor. This competition can occur by both homodimerized dominant-negative receptors and by heterodimeric complexes consisting of a dominant-negative receptor and its canonical equivalent or another binding partner (e.g., the retinoid X receptor (RXR)). Indeed, rVDR1, hTRα2 \[[@r25]; [@r29]\], and hERβcx \[[@r44]; [@r50]\] inhibited the DNA-binding of their canonical receptors in gel shift assays, even though the affinity of the latter two splice variants is significantly reduced compared to the canonical receptors.

The affinity for the cognate response elements differs largely between splice variants, suggesting that this mechanism is not relevant for all splice variants. Rat NOR-2 \[[@r57]\] and hDAX-1α \[[@r28]\] bind to their response element with the same affinity as their cognate canonical receptor in gel shift assays. Other splice variants show significantly reduced DNA binding *in vitro* (hERβcx \[[@r44]; [@r50]\], hGRβ \[[@r47]\], hTRα2 \[[@r25]; [@r29]\], hγORF4 \[[@r31]\], mNurr2 \[[@r51]\]), or do not bind to their response elements at all (hPPARα~tr~ \[[@r17]\], mCAR2 \[[@r9]\], and hCAR(sv5) \[[@r1]\]).

### Heterodimerization

A second mechanism proposed is the formation of dimers between canonical receptors and the dominant-negative form, which are transcriptionally inactive and prevent the formation of active receptor complexes. Several techniques have been used to demonstrate these heterodimers, and in most studies dimerization was observed. Immunoprecipitation studies have shown that hGRβ-hGRα heterodimers occur in human neutrophils \[[@r69]\] and after overexpression of hGRβ in mouse hybridoma cells \[[@r23]\]. Using pull-down assays, hGRβ has been shown to interact with hGRα \[[@r84]\], and hERβcx with hERα (and to a lesser extent with hERβ \[[@r50]\]). Using gel-shift assays, hERβcx has been demonstrated to dimerize with both hERα and hERβ on DNA \[[@r44]\], and similarly rVDR1 and rVDR0 \[[@r15]\], and hTRα2 and hTRα1 \[[@r25]\] have been found to dimerize on DNA (although the latter was shown not to occur in a study by Katz and Lazar \[[@r29]\]).

For nuclear receptors of subfamily 1 (e.g., TR, VDR, CAR, PPAR), that depend on dimerization with RXR for their transactivational activity, splice variants may dimerize with RXR, thereby forming an inactive dimer. However, rVDR1 \[[@r15]\], hTRα2 \[[@r29]\], mCAR2 \[[@r9]\], and hCAR(sv5) \[[@r1]\] were shown to be unable to dimerize with RXR on NREs. Only hγORF4 was shown to dimerize with RXR on DNA \[[@r31]\].

### Competition for coactivators

The third possible mechanism for dominant-negative activity is titration of cofactors by the transcriptionally-inactive receptors. Protein-protein interactions between the dominant-negative receptor isoforms and limited amounts of cofactors can interfere with canonical receptor activity, since these cofactors form the link between the liganded receptor and the basal transcription machinery. Several coactivators that interact with the AF-1 have been suggested to play a role. For example, overexpression of CBP has been shown to prevent the inhibition of hPPARα-induced transactivation by hPPARα~tr~ \[[@r17]\], and overexpression of TIF2/GRIP1 attenuates the suppressive effect of hGRβ on transactivation by hGRα, through interaction with the AF-1 \[[@r8]\]. In contrast, since all described splice variants lack a functional AF-2 domain, it is unlikely that coactivators interacting with this region will bind to these splice variants. Indeed, TIF1α has been shown not to interact with hERβcx in a pull down assay \[[@r50]\], and the coactivators SRC-1, TIF2/GRIP1/SRC-2, ACTR/SRC-3, and DRIP205 have been shown not to interact with hCAR(sv5) in a mammalian two-hybrid assay \[[@r1]\].

*In vivo* relevance; lessons from hGRβ
======================================

The dominant-negative role of hGRβ
----------------------------------

Although evidence for a dominant-negative role for C-terminal splice variants of nuclear receptors is mounting, the physiological role of these receptors may still differ from what has been observed in the *in vitro* studies. All results regarding the repression of the activity of canonical receptors are obtained from studies based on transfection experiments, using vectors containing reporter assays as a measure for transcriptional activity. These experiments provide convincing evidence that the splice variants inhibit (part of) the transactivational activity of their canonical receptor in this experimental setup. However, these receptor variants do not necessarily behave similarly *in vivo*. For instance, reporter assays with vectors containing nuclear receptor response elements (NREs) lack the condense chromatin packaging in which genomic DNA is wrapped *in vivo*. Therefore, NREs in reporter assays are more accessible than promoter regions of endogenous NR target genes. The delicate mechanisms required for transcription initiation, like chromatin remodeling, histone acetylation and methylation are overlooked in this experimental setup.

In addition to these *in vitro* reporter assays, the transcription of endogenous genes has been used as readout in several studies on hGRβ. Li et al. \[[@r38]\] have used the glucocorticoid-induced increase in the expression of MKP-1 mRNA and the decrease of TNFα and IL-6 mRNA expression as readout for the sensitivity to glucocorticoids \[[@r38]\]. This sensitivity was significantly increased in monocytes after treating them with anti-hGRβ siRNA. A similar siRNA experiment was performed in BAL macrophages in which the glucocorticoid-induced increase in MKP-1 transcription was enhanced after knocking down the hGRβ expression \[[@r19]\]. Overexpression of hGRβ in mouse DO-11.10 hybridoma cells resulted in a decreased induction of MKP-1 mRNA following treatment with the synthetic glucocorticoid dexamethasone \[[@r19]\]. In cells derived from human eye tissue (trabecular meshwork cells), overexpression of hGRβ inhibited the dexamethasone-induced increase in the expression of the endogenous genes myocilin and fibronectin \[[@r86]\].

More cell-biological readouts have been used in several other studies on the dominant-negative effect of hGRβ. Increasing the expression of hGRβ by transfection of mouse neutrophils results in a decreased rate of dexamethasone-induced cell death \[[@r69]\]. Overexpression of hGRβ in mouse DO-11.10 hybridoma by viral transduction reduced the inhibition of cell proliferation by several glucocorticoids \[[@r23]\]. Transient overexpression of hGRβ prevented the glucocorticoid-induced inhibition of phagocytosis in human NTM-5 cells \[[@r87]\].

In summary, the dominant-negative activity of hGRβ is well established. It has been shown to inhibit the activity of hGRα in reporter assays. In addition, it has been shown to inhibit glucocorticoid-induced changes in the expression of endogenous genes. Interestingly, this was observed for genes that are activated by glucocorticoids (MKP-1, myocilin, fibronectin) and for genes that are repressed in response to glucocorticoids (TNFα, IL-6), which occurs independently of the receptor's DNA binding ability. Finally, hGRβ has been demonstrated to inhibit glucocorticoid-induced changes in several physiological properties in a number of cell types.

hGRβ as a regulator of transcription independent from hGRα
----------------------------------------------------------

Besides its role as a dominant-negative inhibitor, hGRβ may act as a regulator of transcription independent from hGRα. Three studies show such a role for hGRβ. First, stable overexpression of hGRβ in U-2 OS cells (which do not express hGRα or hGRβ endogenously) resulted in altered transcription of more than 5,000 genes in a microarray study, of which approximately half were increased and half decreased \[[@r37]\]. Second, stable overexpression of green fluorescent protein (GFP)-tagged hGRβ in HeLa cells also showed that hGRβ has intrinsic transcriptional activity \[[@r32]\]. It was shown to regulate the expression of a large number of genes negatively or positively. Third, in transiently transfected reporter assays hGRβ has been shown to, just like hGRα, transrepress the activity of other transcription factors like AP-1 and NF-κB. Overexpression of hGRβ attenuated NF-κB- and AP-1-induced activation in luciferase assays \[[@r20]\] and the GATA3-induced activity of the IL-5 and IL-13 promoters driving a luciferase gene \[[@r30]\]. Thus, although limited data are available, a role for hGRβ independent from hGRα is suggested.

Increased expression of hGRβ and glucocorticoid resistance *in vitro*
---------------------------------------------------------------------

Treatment of cells with pro-inflammatory cytokines like IL-1 or TNFα \[[@r79]\], IL-2 and IL-4 \[[@r35]\], IL-8 \[[@r69]\], IFNα and IFNγ \[[@r73]\], and IL-7 or IL-18 \[[@r53]\] has been shown to induce the expression of hGRβ mRNA and/or protein in several studies. TNFα treatment changes the hGRα:hGRβ protein ratio in HeLa cells from 4:1 to 1:2, resulting from a 4-fold increase in hGRβ and a 2-fold increase in hGRα protein expression \[[@r79]\]. IL-8 was shown to induce the expression of hGRβ protein 2-fold (without affecting hGRα levels) in neutrophils, changing the already low hGRα:hGRβ protein ratio in these cells from 1:4 to 1:8 \[[@r69]\]. The splice factor SRp30 has been suggested to be involved in this process, since it was shown to direct the alternative splicing to hGRβ in these cells \[[@r81]\].

These treatments also resulted in decreased sensitivity to glucocorticoids, as measured by reduced DNA binding of hGRα \[[@r35]\], reduced transactivational activity in reporter assays \[[@r79]\], and reduced transcriptional activity using CD38 repression as a readout \[[@r73]\]. In addition, microbial super-antigens have been demonstrated to induce the expression of hGRβ and to induce glucocorticoid resistance, as demonstrated by a reduced inhibition of the proliferative response to glucocorticoids in human PBMCs \[[@r23]\] and by the inhibition of glucocorticoid-induced IL-2 repression in a nasal explant model \[[@r16]\]. However, in none of the studies mentioned here, has it been demonstrated whether the decrease in sensitivity is due to the increased hGRβ expression, or to other effects of the cytokine treatment.

Several human cell types have been shown to have relatively high levels of hGRβ expression \[[@r49]; [@r59]\]. These high expression levels have been shown to correlate with insensitivity to glucocorticoids. For example, human monocytes have significantly higher hGRβ levels than T cells, and display a slower glucocorticoid induction of MKP-1 and glucocorticoids fail to repress the IL-6 expression in these cells \[[@r38]\]. In addition, in monocytes GRα translocates to the nucleus more slowly in response to glucocorticoid treatment (an effect also seen after overexpression of hGRβ in mouse hybridoma cells \[[@r19]\]).

Increased expression of hGRβ and glucocorticoid resistance *in vivo*
--------------------------------------------------------------------

In a large number of studies, increased hGRβ expression has been shown to correlate with resistance to glucocorticoid treatment in patients suffering from several immune-related diseases, suggesting that hGRβ plays an important role in glucocorticoid resistance in these patients. An increased expression of hGRβ has been demonstrated in various immune cells, particularly T-cells, from glucocorticoid-resistant asthma patients \[[@r19]; [@r21]; [@r35]; [@r68]\]. In addition, in patients suffering from nasal polyposis \[[@r22]\], Crohn's disease \[[@r74]\], ulcerative colitis \[[@r27]; [@r85]\], and leukemia \[[@r66]\], a similar correlation between increased hGRβ levels and glucocorticoid resistance was observed. Goleva et al. \[[@r19]\] demonstrated a causal relationship between hGRβ expression levels and glucocorticoid resistance by decreasing the hGRβ expression level using specific RNA silencing in broncheoalveolar lavage cells from glucocorticoid-resistant asthma patients, which enhanced the glucocorticoid responsiveness in these cells. Finally, a correlation has been found between increased expression of hGRβ and the occurrence of several immune-related diseases. In various immune cells of severe asthma patients \[[@r5]; [@r10]\], and patients suffering from ulcerative colitis \[[@r53]\], leukemia \[[@r66]\], ankylosing spondylitis (Bechterew's disease \[[@r34]\]), nasal polyposis \[[@r22]\], or severe systemic lupus erythematosus \[[@r58]\] increased expression levels of this receptor isoform were found.

A single-nucleotide polymorphism in the glucocorticoid receptor gene in the region encoding the 3'UTR of hGRβ mRNA results in a mRNA with increased stability *in vitro* \[[@r14]; [@r65]\] and this polymorphism is associated with the occurrence of rheumatoid arthritis \[[@r14]\]. This polymorphism is therefore considered to increase the expression of hGRβ in carriers, although this has never been demonstrated. Interestingly, this polymorphism appears to affect only certain glucocorticoid-induced changes in gene expression. In PBMLs derived from carriers, the glucocorticoid-induced transrepression of IL-2 mRNA expression was reduced, but the induction of GILZ mRNA expression by glucocorticoids was not different from non-carriers \[[@r77]\]. In addition, the risk of nasal carriage of *Staphylococcus aureus* is reduced \[[@r76]\], whereas the risk of cardiovascular disease is increased \[[@r75]\].

Thus, relatively high expression levels of hGRβ have been found in cells under certain conditions *in vitro*, in specific cell types *in vivo*, and in patients suffering from a variety of immune-related diseases. In all cases, this increased expression appears to correlate with a decreased sensitivity to glucocorticoids, although the involvement of hGRβ in the observed glucocorticoid resistance has not directly been established in any of these studies.

Ligand binding of hGRβ
----------------------

It has been shown that hGRβ is capable of binding the synthetic hGRα antagonist RU486 \[[@r37]\]. Addition of RU486 increased the fraction of hGRβ residing in the nucleus in COS and U-2 OS cells, whereas a series of 57 related steroids did not affect subcellular localization of hGRβ. A similar effect of RU486 was found for zGRβ in COS and ZF4 (zebrafish fibroblast) cells (Schaaf, unpublished results). Furthermore, RU486 administration alters the regulation of approximately 1,000 genes in hGRβ-overexpressing U-2 OS cells (and not in wild type U-2 OS cells), of which the majority (\~75%) were repressed. However, in a different study, no altered transcriptional activity or nuclear translocation of hGRβ was observed following addition of RU486 in HCT116 cells (derived from a human colon carcinoma) \[[@r32]\]. These studies suggest that RU486 might have cell-specific effects on the activity of hGRβ.

Discussion
==========

In the present review, data on thirteen different C-terminal splice variants have been discussed. Nine human nuclear receptor genes have been demonstrated to show this type of alternative splicing, out of a total of forty-eight nuclear receptor genes in the human genome. The significant number of described C-terminal splice variants suggests that these splice variants play an important role in nuclear receptor functioning. Although many nuclear receptors have been studied in great detail, it is conceivable that several more nuclear receptor genes encode a C-terminal splice variant, but that this has not yet been described for these genes.

The most likely function of these splice variants is to act as a dominant-negative inhibitor of the canonical receptor, since this type of dominant-negative inhibition has been shown for many of the described receptor variants. Ten splice variants have been demonstrated to have dominant-negative activity on their cognate canonical receptor in reporter assays, and only one (mCAR2) failed to display this type of activity in these assays. The human GR β-isoform, the best studied member of this group, was not only studied in reporter assays, but it has also been shown to have dominant-negative activity on endogenous gene regulation by the canonical hGRα, and on glucocorticoid-induced alterations in cell physiology. These data suggest that the data from reporter assays can, at least in part, be extrapolated to the regulation of endogenous genes.

In addition, it is possible that the C-terminal splice variants described in this review function as transcription factors independent from their cognate canonical receptor, since it has been shown that hGRβ is able to regulate gene transcription independent from hGRα \[[@r20]; [@r32]; [@r37]\]. Although this latter activity of hGRβ has not been studied in detail yet, future studies on other C-terminal splice variants may uncover this type of functionality for these receptors, as well.

For the dominant-negative activity of these splice variants, three possible mechanisms of action have been suggested. First, occupation of response elements, although most receptor splice variants showed no or decreased DNA binding. Second, the formation of inactive heterodimers with the canonical receptor. For some C-terminal variants, such dimers with the canonical receptor have indeed been shown for some variants to occur in living cells. Furthermore, DNA binding of several of these dimers was demonstrated *in vitro* using gel shift assays. Third, competition for coactivators has been proposed. Although some variants have been shown to interact with specific coactivators, limited data are available to get a good overview of coactivator binding of the splice variants. Thus, none of the three proposed mechanisms could be excluded, and possibly all three mechanisms play a role. The level at which they contribute to this activity may differ between receptors, and this could be due to structural differences between the splice variants.

Due to their dominant-negative activity, the splice variants may play an important role in the regulation of the activity of their cognate canonical receptor *in vivo*. We hypothesize that these splice variants are capable of blunting (part of) the activity of their respective canonical receptors, which may occur in cells or tissues where the splice variant is expressed at high enough levels for dominant-negative regulation to take place. Since these canonical receptors play important physiological roles, aberrant expression of the splice variants may underlie several pathological conditions. For hGRβ, a role in glucocorticoid resistance and pathogenesis of several immune-related diseases is strongly suggested, as discussed in detail above. For other nuclear receptors, the *in vivo* relevance is less clear. For example, in some studies the presence of hERβcx and hERβ is correlated with better prognosis in breast cancer \[[@r56]; [@r70]\], while in others the presence of hERβcx is of no influence on the development of carcinomas \[[@r82]\]. In addition, allelic variations in intron 8 of the human VDR gene (which is the intron retained for the formation of rVDR1 mRNA) can be used to predict the density of bone \[[@r15]\]. Involvement in tumorigenesis in colorectal cancers has been suggested for the hPPARγ splice variant hγORF4 \[[@r61]\]. These interesting observations indicate that a better understanding of the role of nuclear receptor splice variants may help to elucidate the molecular mechanism of the pathogenesis of a variety of diseases. In addition, the observation that hGRβ is able to bind the synthetic ligand RU486, which alters its activity \[[@r37]\], suggests that opportunities exist to exploit these splice variants as potential drug targets.

Comparison of the structure of these thirteen receptor isoforms yielded two interesting observations. First, two main groups exist. The splice variants of the first group (hGRβ/zGRβ, hERβcx, hTRα1/gTRα1, rVDR1, mCAR2/hCAR(sv5), and hDAX-1α) have a splice-variant-specific tail that starts around helix 10. The variants of the second group (hNurr2, hNOR-2, hPPARα~tr~ and hγORF4) have almost the entire LBD replaced by an alternative sequence. Second, the splice variant-specific C-terminal amino acid sequences are highly heterogeneous (see [Table 2](#table-fn2){ref-type="table"}). They do not appear to show any homology or to share common domains, suggesting that the splice variant-specific amino acid sequence is not important for the dominant-negative activity. Indeed, structure-function studies on hGRβ demonstrated that out of fifteen splice variant-specific amino acids, only two amino acids, that caused a distortion in the (helical) structure of the receptor's C-terminus, were required for the dominant-negative activity of this receptor isoform \[[@r84]\]. These data, together with the lack of similarity between the different C-termini of the different splice variants, suggest that many alternative C-termini may result in dominant-negative activity, but that some specificity exists.

When we compared genomic sequences from human, mouse, chicken, clawed frog and zebrafish, it was shown that the splice sites required for the generation of C-terminal splice variants are relatively well conserved between human and mouse, but not between human and non-mammalian species (data not shown). Of the splice variants that occur in humans and rodents, only hGRβ and hERβcx appear not to be conserved between human and mouse. Interestingly, conservation of the amino acid sequence of the C-terminal tail of the splice variants is very poor, even between human and mouse. Only the sequences specific for TRα2 and CAR2 are more than 50% identical between human and mouse. Thus, similar to our findings when we compared sequences of the different splice variants, we found very little similarity in the C-terminal sequence of splice variants that are orthologs. Both findings suggest low selective pressure on most of these sequences.

In conclusion, many C-terminal splice variants of nuclear receptors exist, which probably play a role as dominant-negative inhibitors of the activity of the canonical receptor. Most of the sequences of their C-terminus may not be critical for this function. We suggest an important role for these receptor isoforms, controlling or fine-tuning the activity of nuclear receptors.
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